Recombinant immunotoxins: new therapeutic agents for cancer treatment

Cancer Detect Prev. 1993;17(2):289-93.

Abstract

We have developed new agents for the treatment of cancer by genetically modifying Pseudomonas exotoxin. We have deleted the cell-binding region of Pseudomonas exotoxin and replaced it with various growth factors or the combining regions of antibodies in a single chain form. These new recombinant molecules are called recombinant toxins. Several different types of recombinant toxins have been produced. B3(Fv)-PE38KDEL is a recombinant toxin that kills many different adenocarcinomas and epidermoid carcinomas. The molecule is now undergoing preclinical development.

MeSH terms

  • ADP Ribose Transferases*
  • Animals
  • Bacterial Toxins / genetics
  • Bacterial Toxins / therapeutic use*
  • Exotoxins / genetics
  • Exotoxins / therapeutic use*
  • Immunotoxins / genetics
  • Immunotoxins / therapeutic use*
  • Mice
  • Neoplasms, Experimental / drug therapy*
  • Neoplasms, Experimental / genetics
  • Pseudomonas aeruginosa Exotoxin A
  • Translocation, Genetic
  • Virulence Factors*

Substances

  • Bacterial Toxins
  • Exotoxins
  • Immunotoxins
  • Virulence Factors
  • ADP Ribose Transferases